Floatz logo

Talzenna

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Prostate Cancer Clinical Trials ConsortiumPhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

229 Active assets in the Metastatic Castration Resistant Prostate Cancer (mCRPC) cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Ding-Wei Ye
Phase 4BBB
Darolutamide
Bayer
Phase 3BB
RADIUM RA-223
University of California, San Francisco
Phase 4BB

View all 50 →

Same molecule, other indications

Talzenna is also rated in:

BRCA2-related cancer predispositionDormant
BB
Indicative ·
68 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
64 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →